A randomized trial of topical menthol for chemotherapy induced neuropathy

局部薄荷醇治疗化疗引起的神经病变的随机试验

基本信息

  • 批准号:
    8759581
  • 负责人:
  • 金额:
    $ 6.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-01 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Due to major advances in early detection and therapy, an estimated 12 million cancer survivors are living in the United States today. Unfortunately, most cancer therapies are known to carry a substantial risk of adverse long-term effects. One of the most common and debilitating adverse effects is chemotherapy-induced peripheral neuropathy (CIPN), which is associated with many widely used anticancer drugs. The optimal treatment for persistent CIPN remains unknown. Symptomatic treatments include antidepressants, anticonvulsants, non-narcotic and narcotic analgesics. While antidepressants have shown moderate benefit, their use has been limited due to side effects and significant drug to drug interactions. A few small unblinded studies of topical menthol suggest a possible benefit in relieving neuropathy. We hypothesize that six week treatment with 2% topical Menthol application twice a day will decrease persistent neuropathic pain following adjuvant chemotherapy with a Taxane or Oxaliplatin-based regimen. We plan to test this hypothesis with a two arm double blind, placebo controlled, randomized pilot study following adjuvant therapy in breast and colon cancer patients. Our aims are (1) To assess whether six week treatment with twice daily topical Menthol application will decrease persistent neuropathic pain; (2) To evaluate the effect of topical Menthol compared to placebo on global measures of neuropathy; (3) To evaluate the effect of topical Menthol on objective sensory and motor functional tests; and (4) To perform an exploratory analysis evaluating the interaction between treatment and chemotherapy type. To date, we have not been successful at treating or preventing CIPN. This study evaluates the use of a promising and readily available, low cost and well tolerated topical intervention. If found beneficial, this treatment addressing the putative underlying mechanism of CIPN, may bring us one step closer to improving the lives of cancer survivors.
描述(由申请人提供):由于早期检测和治疗的重大进展,估计今天有1200万癌症幸存者生活在美国。不幸的是,已知大多数癌症治疗具有长期不良反应的重大风险。化疗引起的周围神经病变(CIPN)是最常见和最令人衰弱的副作用之一,与许多广泛使用的抗癌药物有关。持续性CIPN的最佳治疗方法仍然未知。对症治疗包括抗抑郁药、抗惊厥药、非麻醉性和麻醉性镇痛药。虽然抗抑郁药显示出适度的益处,但由于副作用和显著的药物相互作用,它们的使用受到限制。一些小的非盲研究表明,局部薄荷醇可能有利于缓解神经病变。我们假设,用2%的局部美托洛尔治疗6周,每天两次,将减少紫杉烷或奥沙利铂为基础的方案辅助化疗后的持续神经性疼痛。我们计划在乳腺癌和结肠癌患者接受辅助治疗后进行一项双臂双盲、安慰剂对照、随机化的初步研究,以检验这一假设。我们的目的是(1)评估用每日两次局部施用美托洛尔的六周治疗是否将减少持续性神经性疼痛;(2)评估与安慰剂相比,局部美托洛尔对神经病的总体测量的效果;(3)评估局部美托洛尔对客观感觉和运动功能测试的效果;(4)探索性分析治疗与化疗类型之间的相互作用。到目前为止,我们还没有成功地治疗或预防CIPN。本研究评估了一种有前途的、容易获得的、低成本的、耐受性良好的局部干预的使用。如果发现有益的话,这种治疗方法解决了CIPN的潜在机制,可能会使我们更接近改善癌症幸存者的生活。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAWN HERSHMAN其他文献

DAWN HERSHMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAWN HERSHMAN', 18)}}的其他基金

Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and Reduce Refill Rates after Cancer Surgery
药丸分配系统在增加未使用阿片类药物的处置并降低癌症手术后补充率方面的功效
  • 批准号:
    10665967
  • 财政年份:
    2023
  • 资助金额:
    $ 6.96万
  • 项目类别:
Intervention to iMProve AdherenCe equiTably (IMPACT TRIAL)
公平地提高依从性的干预(影响试验)
  • 批准号:
    10657754
  • 财政年份:
    2021
  • 资助金额:
    $ 6.96万
  • 项目类别:
Intervention to iMProve AdherenCe equiTably (IMPACT TRIAL)
公平地提高依从性的干预(影响试验)
  • 批准号:
    10437181
  • 财政年份:
    2021
  • 资助金额:
    $ 6.96万
  • 项目类别:
Intervention to iMProve AdherenCe equiTably (IMPACT TRIAL)
公平地提高依从性的干预(影响试验)
  • 批准号:
    10494225
  • 财政年份:
    2021
  • 资助金额:
    $ 6.96万
  • 项目类别:
Admin Core
管理核心
  • 批准号:
    10933782
  • 财政年份:
    2021
  • 资助金额:
    $ 6.96万
  • 项目类别:
Delays in Acquisition of Oral Antineoplastic Agents
口服抗肿瘤药物的获取延迟
  • 批准号:
    9975367
  • 财政年份:
    2020
  • 资助金额:
    $ 6.96万
  • 项目类别:
Molecular Oncology Training Program
分子肿瘤学培训计划
  • 批准号:
    9316338
  • 财政年份:
    2016
  • 资助金额:
    $ 6.96万
  • 项目类别:
Molecular Oncology Training Program
分子肿瘤学培训计划
  • 批准号:
    10089670
  • 财政年份:
    2016
  • 资助金额:
    $ 6.96万
  • 项目类别:
Using SWOG-Medicare database to evaluate long-term toxicities of cancer survivors
使用 SWOG-Medicare 数据库评估癌症幸存者的长期毒性
  • 批准号:
    8620619
  • 财政年份:
    2013
  • 资助金额:
    $ 6.96万
  • 项目类别:
Using SWOG-Medicare database to evaluate long-term toxicities of cancer survivors
使用 SWOG-Medicare 数据库评估癌症幸存者的长期毒性
  • 批准号:
    8997455
  • 财政年份:
    2013
  • 资助金额:
    $ 6.96万
  • 项目类别:

相似海外基金

3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
  • 批准号:
    10556192
  • 财政年份:
    2023
  • 资助金额:
    $ 6.96万
  • 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
  • 批准号:
    10315227
  • 财政年份:
    2021
  • 资助金额:
    $ 6.96万
  • 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
  • 批准号:
    443988
  • 财政年份:
    2021
  • 资助金额:
    $ 6.96万
  • 项目类别:
    Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
  • 批准号:
    20K09011
  • 财政年份:
    2020
  • 资助金额:
    $ 6.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
  • 批准号:
    19K09130
  • 财政年份:
    2019
  • 资助金额:
    $ 6.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
  • 批准号:
    19K18225
  • 财政年份:
    2019
  • 资助金额:
    $ 6.96万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
  • 批准号:
    18K16337
  • 财政年份:
    2018
  • 资助金额:
    $ 6.96万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
  • 批准号:
    10005254
  • 财政年份:
    2018
  • 资助金额:
    $ 6.96万
  • 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
  • 批准号:
    9763320
  • 财政年份:
    2018
  • 资助金额:
    $ 6.96万
  • 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
  • 批准号:
    18K07341
  • 财政年份:
    2018
  • 资助金额:
    $ 6.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了